Media Articles Related to Exforge (Amlodipine / Valsartan)
Deaths from pulmonary hypertension have increased, say CDC
Source: Hypertension News From Medical News Today [2014.04.04]
A study from the CDC finds that deaths from pulmonary hypertension - high blood pressure in the arteries leading from the heart to the lungs - have increased over the past decade.
Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)
Source: MedicineNet Brain Aneurysm Specialty [2014.04.02]
Title: Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)
Category: Diseases and Conditions
Created: 11/8/1998 8:47:00 PM
Last Editorial Review: 4/2/2014 12:00:00 AM
Children with glomerular kidney disease more likely to have hypertension as adults
Source: Hypertension News From Medical News Today [2014.03.20]
Men who as children had glomerular disease, a disorder of the portion of the kidney that filters blood and one that usually resolves with time, were more likely than men without childhood...
Guidelines on the management of pulmonary hypertension of sickle cell disease
Source: Hypertension News From Medical News Today [2014.03.18]
The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from...
Source: MedicineNet Congestive Heart Failure Specialty [2013.11.25]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/25/2013 12:00:00 AM
Published Studies Related to Exforge (Amlodipine / Valsartan)
Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension. [2011.09]
Achieving target blood pressure (BP) is influenced by baseline BP. Post hoc analyses of a placebo-controlled trial of amlodipine/valsartan versus monotherapies were conducted to characterize BP control by baseline BP...
Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups. [2011.07]
Combination therapy may reduce racial/ethnic differences in response to antihypertensives. In this post-hoc analysis, we evaluated treatment response by race/ethnicity among hypertensive adults enrolled in a 12-week, double-blind study in which patients previously uncontrolled (mean sitting systolic blood pressure [MSSBP] >/=150 and <200 mm Hg) on angiotensin receptor blocker (ARB) monotherapy (other than valsartan) for 28 days or more (n = 728) were randomized to amlodipine/valsartan 10/320 mg (intensive) or 5/160 mg (moderate)...
Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. [2011.06]
The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort, parallel-group study... All treatments were safe and well tolerated.
The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. [2011.04]
OBJECTIVES: Ambulatory blood pressure monitoring (ABPM) has greater predictive value than office blood pressure (BP) with respect to hypertension-related target-organ damage and morbidity. ABPM in a subset of 80 patients from the Exforge Target Achievement trial (N=728) was used to compare the efficacy of intensive-treatment and moderate-treatment regimens of amlodipine/valsartan, and to determine whether treatment differences could be better assessed with ABPM than with office or home BP. Home BP was measured on the morning of clinic visits to minimize differences that timing might have on home versus office BP measures... CONCLUSION: In this first randomized trial evaluating the effects of intensive versus moderate dosing of the combination of amlodipine/valsartan, our data suggest that ABPM was a better method for assessing between-treatment differences than clinic or home BP recordings, although measurement of home BP as a single recording was a limitation of our trial.
Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. [2011.04]
OBJECTIVES: This study compared the effects of morning and evening dosing of amlodipine/valsartan combination on 24-h blood pressure (BP) in patients uncontrolled by amlodipine (5 mg)... CONCLUSION: These results indicate that, in patients with BP uncontrolled by amlodipine (5 mg), morning and evening treatment with amlodipine/valsartan combination have similar effects on circadian BP, especially when 24-h mean values are considered.
Clinical Trials Related to Exforge (Amlodipine / Valsartan)
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
The purpose of this study is to evaluate long-term safety and tolerability of once daily
administration of the combination of Valsartan and Amlodipine 80/5 mg for 52 weeks in
patients with essential hypertension.
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension [Completed]
The purpose of this study is to evaluate the safety and efficacy of fixed combination of
valsartan (40 mg and 80 mg) and amlodipine (2. 5 mg and 5 mg), valsartan and amlodipine alone,
and placebo in reducing blood pressure. The study will investigate the dose response
relationship for the combinations, monotherapies and placebo.
Effectiveness of EXforge® and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients [Recruiting]
This study is to demonstrate that valsartan/amlodipine 80/5 mg has superior efficacy
compared with nifedipine 30mg alone in reducing the mean sitting diastolic blood pressure
(MSDBP) and mean sitting systolic blood pressure (MSSBP) from baseline in patients with mild
to moderate hypertension not adequately controlled with monotherapy.
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension. [Completed]
This trial will compare valsartan and amlodipine combination therapies to both valsartan and
amlodipine, and placebo for the treatment of hypertension.
The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
The purpose of this study is to determine the effects of treatment with valsartan +
amlodipine to a target systolic blood pressure (SBP)<130 mmHg compared to the Joint National
Commission on the Treatment of Hypertension 7 recommended target SBP of <140 mmHg on the
intrinsic diastolic properties of the myocardium in patients with hypertension and
echocardiographic evidence of diastolic dysfunction.
Reports of Suspected Exforge (Amlodipine / Valsartan) Side Effects
Blood Pressure Increased (85),
Oedema Peripheral (57),
Cerebrovascular Accident (57),
Diabetes Mellitus (44),
Dyspnoea (33), more >>